News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II (World)
PRANA Biotechnology (PRAN) Release: PBT2 Recommended For Orphan Designation In Europe 4/28/2015
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015
Imperial Innovations Release: Autifony Therapeutics Recruits First Patient Into Phase IIa Trial For Age Related Hearing Loss 4/27/2015
NeuroVive: FIrst Patient Enrolled In Clinical Phase II Study For Kidney Protection During Heart Surgery 4/27/2015
Gilead (GILD) Announces Results From Studies Evaluating Sofosbuvir-Based Regimens In Chronic Hepatitis C Patients With Genotypes 2-5 4/27/2015
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1450 In Staphylococcal Skin Infections 4/23/2015
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome 4/23/2015
Teva (TEVA) And Active Biotech AB (BTPC) Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS 4/23/2015
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy 4/22/2015
NeuroVive: Clinical Phase II Study With Neurostat For Traumatic Brain Injury Passes Safety Evaluation 4/21/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
Biothera Immunotherapy Combination Results In Tumor Reduction During Maintenance Phase Of Non-Small Cell Lung Cancer Study 4/15/2015
Pharmalink AB Phase II Trial Of Nefecon Halted Early 4/14/2015
Mechanism Of Action Of ABIVAX's First-in-class Anti-HIV Drug Published Today In Peer-Reviewed Journal Retrovirology 4/13/2015
Admedus Herpes Phase II – First Dosing To Commence 4/10/2015
Onxeo Release: Belinostat Phase I/II Results In Soft Tissue Sarcoma To Be Presented At The 2015 Annual ASCO Meeting 4/9/2015
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015
Alkermes (ALKS) Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 4/6/2015
AstraZeneca PLC (AZN)'s Failed Cancer Drug Finds New Life in Alzheimer’s Treatment 4/3/2015
Clementia Advances Phase 2 Clinical Trial Of Palovarotene In Fibrodysplasia Ossificans Progressiva Based On Recommendations From Data Monitoring Committee (DMC) 4/2/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015
Hutchison Medipharma's Cancer Drug Meets Endpoint In Phase II Trial 4/1/2015
RedHill Biopharma Ltd. (RDHL) Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech 3/31/2015
Innate Pharma (IPH.PA ) : DSMB Recommends Continuation Of Effikir Trial With Two Arms 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
NIH Release: Ebola Test Vaccines Appear Safe In Phase 2 Liberian Clinical Trial 3/27/2015
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015
Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
VBL Therapeutics (VBLX) Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Interim Results From Phase IIb Clinical Trial For Knee Osteoarthritis Stem Cell Rejoin Therapy 3/25/2015
Mologen AG (MOLGF.PK): Start Of Pivotal Study For Cancer Immunotherapy MGN1703 Influences 2014 Annual Result 3/25/2015
Pluristem Therapeutics (PSTI) Announces Key Strategic Objectives For Development Of PLX-R18 In Hematopoietic Indications 3/24/2015
MediGene AG (MDGEF.PK) Starts Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 3/24/2015
Can-Fite BioPharma (CFBI) Signs Multi-Million Dollar Distribution Agreement For CF101 In Canada With Cipher Pharmaceuticals (DND.TO) 3/23/2015
Cipher Pharmaceuticals (DND.TO) Acquires Canadian Rights To Novel Treatment For Psoriasis And Rheumatoid Arthritis 3/23/2015
OncoGenex Pharmaceuticals Inc. (OGXI) To Report Financial Results For Fourth Quarter And Year End 2014 On March 26, 2015 3/23/2015
Teva (TEVA)'s TEV-48125 Meets Primary And Secondary Endpoints In Episodic Migraine Study, Demonstrating Treatment Concept After A Single Dose 3/23/2015
Bone Therapeutics Treats First Patients In ALLOB Phase IIA Spinal Fusion Trial 3/23/2015
Dilaforette Receives Orphan Drug Designation In The U.S. For Sevuparin In Sickle-Cell Disease 3/20/2015
Dignity Sciences Presents Late-Breaking News Abstract On DS107 At American Academy of Dermatology Annual Meeting 3/20/2015
BioInvent (BOVNF) Confirms Clinical Strategy For BI-505 And Plans To Conduct Phase IIa Trial In Multiple Myeloma Post-Stem Cell Transplant Patients In The U.S. 3/19/2015
Hemostemix Expands Clinical Trial For Critical Limb Ischemia (CLI) To Four Sites In South Africa, Treats First South African Participant 3/19/2015
Creabilis' CT327 Phase 2b Data Published In Acta Dermato-Venereologica, Strengthens Scientific Advisory Board 3/19/2015
Ascletis, Inc. Reports Strong Phase II Data For Hepatitis C Drug 3/18/2015
Imperial Innovations' Cell Medica Granted Orphan Drug Designation For Novel Cellular Therapy And Treats First Lymphoma Patient In CITADEL Phase II Trial 3/18/2015
Ablynx (ABLYF) Initiates The First Of Two Phase IIb Ra Studies With Its Anti-Il-6R Nanobody, Partnered With AbbVie (ABBV) 3/17/2015
NovImmune SA Release: New Drug Begins Testing As First-Line Treatment For Fatal Childhood Disease 3/16/2015
VAXIL Receives EU Orphan Drug Designation For Immucin For The Treatment Of Multiple Myeloma 3/16/2015
Yisheng Biopharma Co., Ltd. Release: A New Therapeutic Vaccine Successfully Developed Against Rabies 3/16/2015
Cytokinetics, Inc. (CYTK) Announces Completion Of Enrollment In COSMIC-HF 3/13/2015
AB Science (AB.PA) : Positive Phase II Clinical Study Data Of Masitinib In Triple Negative Breast Cancer 3/13/2015
Theravance Biopharma Announces Initiation Of Phase 2b Study Of Velusetrag (TD-5108) For The Treatment Of Gastroparesis 3/13/2015
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Elafin Combined With Cyclosporine Promises To Overcome Limitations Of Cyclosporine For Preventing Irreversible Damage To Transplanted Organs 3/12/2015
Benitec Biopharma Doses Fourth Patient In Hepatitis C Trial 3/11/2015
Herantis Pharma's Phase 2 Dry Eye Study Recruitment Completed Ahead Of Schedule 3/11/2015
Galmed Pharmaceuticals Announces The Beginning Of Enrollment In Its Phase IIb ARREST Trial For The Treatment Of NASH, As Well As The Expansion Of The Study To The United States 3/9/2015
ORYX Successfully Completes Phase 1/2a Trial With Therapeutic Vaccine Vicoryx To Treat HPV-Associated Cancers 3/9/2015
Probiodrug AG Announces Enrolment Of First Patient In Phase 2 Study Of Novel Treatment For Alzheimer’s Disease 3/9/2015
Hua Medicine Files To Start U.S. Trial Of Novel Diabetes Drug 3/9/2015
BioLineRx Ltd. Announces Underwritten Public Offering Of Its American Depositary Shares 3/6/2015
AEterna Zentaris (AEZS) Announces Pricing Of US$37 Million Public Offering Of Common Shares And Warrants 3/6/2015
Hemostemix Expands Clinical Trial For Treating Critical Limb Ischemia To The Peter Munk Cardiac Centre At Toronto General Hospital 3/6/2015
ViroMed Co., Ltd. dba VM BioPharma: A Phase 2 Study Done At Northwestern Hospital Shows Potential Relief For Diabetics With Painful Condition 3/6/2015
Pharma Two B Completes Enrollment In Phase IIb Study Of P2B001 For Parkinson's Disease 3/4/2015
ORYX' Therapeutic Vaccine Micoryx Successfully Completes Phase 1/2a Trial To Treat MSH-H Colorectal Cancer 3/4/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Primary Peritoneal Cancer 3/3/2015
Alizé Pharma Launches Phase 2 Clinical Trial Of AZP-531 In Prader-Willi Syndrome 3/2/2015
BioLineRx Ltd. Announces Regulatory Submission For Phase 2b Trial For Novel AML Consolidation Treatment 3/2/2015
Opsona Therapeutics Ltd. Commences Part B Of Phase II Study Of Blocking Toll-Like Receptor 2 In Extended Criteria Donor Renal Transplant Recipients At High Risk Of Early Graft Dysfunction 3/2/2015
ABIVAX Recruits First Patient In A Pivotal Phase 2b/3 Clinical Trial With ABX203, A Novel Immunotherapy Against Chronic Hepatitis B 2/26/2015
Phosphate Therapeutics Announces Completion Of Subject Recruitment Into The PEACH Pivotal Phase 2 Study Of Its Novel Phosphate Binder (PT20) For The Treatment Of Hyperphosphataemia 2/26/2015
ISA Pharmaceuticals Announces Start Of First Phase 1/2 Clinical Trial Of Its SLP®-AMPLIVANT® Conjugates 2/26/2015
Dilafor Announces Positive Results From A Multi Dosing Safety And Pharmacokinetic Clinical Study 2/25/2015
Teva Pharmaceutical Industries (TEVA) Announces Positive Results For TEV-48125 In Phase IIb Chronic Migraine Study Meeting Primary And Secondary Endpoints 2/24/2015
Emisphere Technologies, Inc. (EMIS) Highlights Positive Phase 2 Og217sc Data From Eligen Licensee Novo Nordisk A/S (NVO) 2/23/2015
Addex Therapeutics (ADXN.SW) Initiates Dipraglurant Receptor Occupancy Clinical Study In Collaboration With Johns Hopkins University With Funding From The Michael J. Fox Foundation 2/23/2015
Galapagos NV (GLPG.BR) Reports That The Last Patient In Darwin 1 Has Completed 12 Weeks Of Treatment 2/23/2015
Anergis Presents Sustained Efficacy Data From Its Allert Phase 2b Trial At The AAAAI Annual Meeting 2/23/2015
Shares Surge as Novo Nordisk A/S (NVO) Shows Off Positive Trial Data for Oral Insulin 2/23/2015
Novo Nordisk A/S (NVO) Announces Positive Results For Phase 2 Trial With Oral Semaglutide In People With Type 2 Diabetes 2/20/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Completion Of Enrollment In Randomized Phase 2 Colorectal Cancer Study 2/18/2015
BioTie Therapies Corp.: BTT1023 Receives Positive Opinion For Orphan Drug Designation From COMP 2/17/2015
VBL Therapeutics (VBLX) Reports Topline Results From Phase 2 Studies Of VB-201 In Psoriasis And Ulcerative Colitis 2/17/2015
Protalix Biotherapeutics, Inc. (PLX) Presents Additional Positive Phase I/II Interim Clinical Data On PRX-102 For Fabry Disease At The WORLD Symposium 2/12/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Designation From The U.S. FDA For Ovarian Cancer 2/11/2015
BIOCEO15: BioLineRx Ltd. CEO Touts New Celiac Drug, Fleshes Out Novartis AG (NVS) Partnership Terms 2/11/2015
Amarantus BioSciences, Inc. Announces Publication In BRAIN Of Eltoprazine Phase 2a Clinical Study For Treating Parkinson's Disease Levodopa-Induced Dyskinesia 2/10/2015
Advanced Inhalation Therapies Receives Orphan Drug Designation Of Its Proprietary High Dose Formulation Of Nitric Oxide For Adjunctive Treatment Of Cystic Fibrosis 2/9/2015
Helsinn Healthcare SA And Zealand Pharma  (ZEAL.CO) Announce The Advance Of Elsiglutide Into Phase 2B Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Zealand Pharma  (ZEAL.CO) And Helsinn Healthcare SA Announce The Advance Of Elsiglutide Into Phase IIB Development For The Prevention Of Chemotherapy-Induced Diarrhea 2/5/2015
Adocia Reports Positive Results From Phase 2a Clinical Study Of Fast-Acting Insulin, HinsBet 2/5/2015
Qu Biologics Enrolls First Two Participants In Phase 2a Clinical Trial For Lung Cancer 2/4/2015
AB Science (AB.PA): Positive Phase 2 Clinical Study Data Of Masitinib In Second-Line Metastatic Stomach Cancer 2/3/2015
BrainStorm Cell Therapeutics Inc. Announces Positive DSMB Recommendation In Ongoing Phase 2 Trial With NurOwn™ In ALS 2/3/2015
Immuron Release: Patient Recruitment Commenced For Phase 2 NASH Trial 2/3/2015
Genmab A/S (GEN.CO) Announces Preliminary Results In Phase 2 Study Of Daratumumab In Double Refractory Multiple Myeloma 2/3/2015
Treatment Of The First HIV Positive Patient In ABIVAX's Phase 2a Clinical Trial With ABX464 2/2/2015
Biomay AG Reports Positive Phase 2b Data With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 1/28/2015
Pivotal Therapeutics Inc. Receives Final Approval For Phase 2a Clinical Trial With PVT-100 1/27/2015
Genticel To Continue Per Protocol Its Phase 2 Clinical Study With Procervix After 2nd Review By The DSMB 1/26/2015
GlaxoSmithKline (GSK)'s Long-Awaited Ebola Vaccine Due to Arrive in Liberia 1/26/2015
TauRx Therapeutics Release: First Evidence Of Potential Efficacy Of Tau Aggregation Inhibitor Therapy In Alzheimer's Disease 1/20/2015
AM-Pharma Starts Adaptive Phase 2 Trial Of Recap In Acute Kidney Injury 1/20/2015
Bone Therapeutics Demonstrates Efficacy In First Patient Cohort In ALLOB® Phase I/IIA Delayed-Union Trial 1/19/2015
Mesoblast Limited (MSB.AX) Reports Positive 24 Month Results In Phase 2 Trial For Chronic Low Back Pain And Initiation Of Phase 3 Program At J.P. Morgan Healthcare Conference 1/15/2015
Amarantus BioSciences, Inc. Announces Positive Data From 140 Subject LP-002 Clinical Study Of Lympro Test® Confirming Statistically Significant Markers For Alzheimer's 1/15/2015
Newron Pharmaceuticals (NWRN) Initiates Phase 2 Study Of sNN0031 In Patients With Parkinson’s disease 1/14/2015
Clementia Opens Clinical Trial Site In Europe For Phase 2 Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 1/12/2015
DelMar Pharmaceuticals Provides Update On VAL-083 Clinical Trial And Outlines Corporate Objectives For 2015 1/12/2015
MerLion Pharmaceuticals Pte Ltd’s Finafloxacin Shows Positive Phase 2 Results In Complicated Urinary Tract Infections 1/9/2015
Bio Blast Provides Update On Clinical Trial Of Cabaletta™ For Occulopharyngeal Muscular Dystrophy (OPMD) 1/8/2015
GW Pharmaceuticals (GWPH) Provides Update On Epidiolex® Program In Treatment Resistant Childhood Epilepsies 1/8/2015
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Receives Clearance From Health Canada For Diabetes Clinical Trial 1/8/2015
Galapagos Starts Phase 2 Trial With GLPG1205 In Ulcerative Colitis Patients 1/8/2015
Pharming Group (PHGUF.PK) And Salix Pharmaceuticals, Ltd. (SLXP) Announce First Patient Treated In Clinical Study Of Ruconest® For Prophylaxis Of Hereditary Angioedema 1/8/2015
Herantis Pharma Has Initiated Phase 2 Study With Cis-UCA Eye Drops In Patients With Dry Eye Syndrome, Results Expected In Q3/2015 1/7/2015
Benitec, Inc. (BLT.AX) Advances Hepatitis C Clinical Trial 1/7/2015
Otic Pharma Announces Positive Results From A Phase 2 Trial Of Foamotic Externa, Once-A-Day, Single Antibiotic, Steroid Free Product For Acute Otitis Externa (AOE) 1/7/2015
Gamida Cell Ltd.'s NiCord® Receives FDA And European Medicines Agency Orphan Drug Designation 1/6/2015
BrainStorm Cell Therapeutics Inc. Announces Final Analysis Of Phase 2a ALS Study Showing Nearly All Subjects Experienced Clinical Benefit From NurOwn™ 1/5/2015
NeuroDerm Ltd. (NDRM) Shares Double as Parkinson's Drug Shows Promise in Phase 2 Study 1/2/2015
NeuroDerm Ltd. (NDRM) Announces Topline Results Of Phase 2a Pharmacokinetic Study Of ND0612H And ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease 12/31/2014
NeuroLifeSciences Release: Redefining ADHD: A New Approach & A Shift Of Paradigm In ADHD Therapeutics 12/23/2014
BioTie Therapies Corp. Announces Start Of Syn120 Phase 2a Trial In Parkinson's Disease Dementia And Provides Outlook Update For Near Term Pipeline Events 12/23/2014
Second Phase Of GlaxoSmithKline (GSK)'s Ebola Vaccine Delayed 12/22/2014
AB Science (AB.PA): Report Of Positive Clinical Study Data In Metastatic Colorectal Cancer 12/19/2014
Amarantus BioSciences, Inc. Submits Orphan Drug Designation Application To U.S. FDA For Treatment Of Retinal Artery Occlusion With Product Candidate MANF 12/19/2014
Nuvo Research Inc. (NRI.TO) Reports That All Patients Have Completed Phase 2 Study Of WF10 For The Treatment Of Allergic Rhinitis 12/18/2014
D-Pharm Ltd. Achieves Primary End-Point In Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 12/18/2014
Ablynx (ABLYF) Opens Recruitment For First-In-Infant Phase 2a Study With Its Anti-Rsv Nanobody, ALX-0171 12/17/2014
Pivotal Therapeutics Inc. Release: VASCAZEN POMEGA Phase 2a Trial Protocol Cleared Clinical Evaluation By French FDA 12/17/2014
First Patient Treated In Mapi Pharma's Phase 2a Clinical Trial Of GA Depot For Relapsing Remitting Multiple Sclerosis (RRMS) 12/17/2014
Poxel Announces Positive Top Line Results For Its Antidiabetic Agent Imeglimin In A Phase 2b Dose-Ranging Trial 12/17/2014
GENFIT Corp. (ALGFT): Gft505 Treatment Prevents Evolution To Cirrhosis 12/16/2014
VBL Therapeutics (VBLX) Announces Last Patient Out In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 12/15/2014
Can-Fite BioPharma (CFBI) Release: Second Part Of The Glaucoma Phase 2 Study Has Been Approved In A European Country 12/15/2014
Merck & Co. (MRK),NewLink Genetics Ebola Trial Suspended After Patients Complain Of Joint Pain 12/12/2014
TWi Pharmaceuticals, Inc. Receives Approval Of Protocol For Its Drug Ac-201 Controlled-Release Tablet, Phase 2 Clinical Trial In Both The United States And Taiwan 12/12/2014
Kamada Ltd. (KMDA) Announces Positive Interim Results From Phase 1/2 Clinical Study Of Its Human Alpha-1 Antitrypsin To Treat Graft-Versus-Host Disease Presented At American Society of Hematology Annual Meeting 12/11/2014
Merck Announces Positive Data Investigating The Use Of Pembrolizumab In Patients With Advanced Triple-Negative Breast Cancer At 2014 San Antonio Breast Cancer Symposium 12/10/2014
Kiadis Pharma Presents Positive Data From A Pre Specified Interim Analysis Of The Phase 2 Clinical Program With Its Lead Product ATIR 12/9/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
Generon (Shanghai) Corporation Ltd. Presents The Global Phase 2 Study Results For F-627 (Benegrastim) At American Society of Hematology 56th Annual Meeting At San Francisco 12/8/2014
QLT Inc. (QLTI) Announces Results From Proof-of-Concept Trial With Oral Synthetic Cis-Retinoid (QLT091001) In Adult Subjects With Impaired Dark Adaptation And/Or Impaired Low Luminance Vision 12/5/2014
Genmab A/S (GEN.CO) Announces Phase 2 Study Of Daratumumab In Non-Hodgkin's Lymphomas 12/4/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Milestone Pharmaceuticals Announces Positive Phase 1 Data For MSP-2017; Supports Advancement Into Phase 2 In PSVT Patients 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Clementia Pharmaceuticals Receives European Medicines Agency Orphan Medicinal Product Designation For Palovarotene For The Treatment Of Fibrodysplasia Ossificans Progressiva 11/21/2014
Clovis Oncology (CLVS) Release: Initial Data From Ongoing Phase 2 ARIEL2 Study Of Rucaparib In Ovarian Cancer Demonstrate Encouraging Clinical Activity And Safety In Both BRCA Mutant And Brcaness Patients 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
Autifony Therapeutics Announces Initiation Of Phase 2a Study For First-In-Class Drug To Treat Tinnitus 11/20/2014
Cynapsus Therapeutics (CYNAF) Announces Positive Top-Line Results From CTH-105 Phase 2 Study Of APL-130277 For The Treatment Of OFF Episodes In Patients With Parkinson's Disease 11/19/2014
Bio Blast Pharma Receives Orphan Drug Designation From U.S. FDA For Cabaletta For The Treatment Of Spinocerebellar Ataxia Type 3 11/19/2014
BIND Therapeutics (BIND) Presents Positive Phase 2 Results Highlighting Potential Of BIND-014 As Novel Anti-Cancer Treatment At Q3W Dosing Schedule For Patients With Non-Small Cell Lung Cancer At 26th EORTC-NCI-AACR Annual Symposium 11/19/2014
Tokai Pharmaceuticals (TKAI) Presents Updated Interim Galeterone ARMOR2 Data Showing Activity In Patients With Castration-Resistant Prostate Cancer (CRPC) Including Those Showing A Variant Form Of Prostate Cancer Resistant To Hormone Therapy 11/19/2014
ObsEva Announces The Initiation Of A Pivotal Phase 2 Study To Evaluate OBE001 For Improving Embryo Implantation And Clinical Pregnancy Rate In Women Undergoing IVF/ICSI 11/18/2014
Merck & Co. (MRK) Announces Positive Study Investigating The Use Of KEYTRUDA® (pembrolizumab) Compared To Chemotherapy In Patients With Ipilimumab-Refractory Advanced Melanoma 11/17/2014
Wilson Therapeutics Announces Start Of Phase 2 Study To Evaluate The Efficacy And Safety Of WTX101 In Newly Diagnosed Wilson Disease Patients 11/17/2014
Mesoblast Limited (MSB.AX)'s Phase 2 Trial Results In Chronic Low Back Pain Presented At North American Spine Society Annual Meeting 11/13/2014
Galmed Pharmaceuticals Announces First Administration Of Aramchol In Its Phase 2a Trial For The Treatment Of Cholesterol Gallstones 11/13/2014
GenKyoTex S.A. Completes Enrollment Into Phase 2 Trial Of NOX1&4 Inhibitor GKT137831 In Diabetic Nephropathy 11/13/2014
Galapagos NV (GLPG.BR) Completes Recruitment For Darwin 1 Study With GLPG0634 (Filgotinib) In RA 11/12/2014
AB Science (AB.PA): The Data And Safety Monitoring Board Recommends The Continuation Of The Phase 2 Study With Masitinib In Advanced Hepatocellular Carcinoma 11/12/2014
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Soft Tissue Sarcoma 11/12/2014
Enzymotec Initiates Clinical Study Of Vayarin® In Adult ADHD 11/11/2014
Prima Biomed (PRR.AX) Release: CVac Demonstrates Overall Survival Benefit In Second Remission Ovarian Cancer 11/6/2014
D-Pharm Ltd. Reports First Results From Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With tPA 11/4/2014
BioLineRx Ltd. Files Protocol Amendment To Phase 2 Study For AML Treatment Based On Encouraging Efficacy And Strong Safety Profile 11/3/2014
Onxeo: Positive Phase 2 Preliminary Results Of Validive® For The Prevention Of Severe Oral Mucositis In Head And Neck Cancer Patients 10/31/2014
Kiadis Pharma's Lead Product ATIR™ Granted Orphan Drug Designation By European Medicines Agency For The Treatment Of Acute Myeloid Leukemia 10/30/2014
Apogenix- Positive Results From APG101 Phase 2 Clinical Trial Published In Clinical Cancer Research 10/28/2014
Moberg Pharma AB (Formerly known as Moberg Derma): First Patient Included In Phase 2 Study Of BUPI, A Novel Topical Formulation For Treatment Of Oral Pain 10/28/2014
TxCell Achieves Positive Results For Col-Treg In A Model Of Autoimmune Uveitis 10/28/2014
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/28/2014
Generex Biotechnology Corporation (GNBT) Announces Presentations Correlating Immunological Response With Reduced Recurrence In Phase 2 Study Of AE37 Breast Cancer Vaccine In Patients At The American College of Surgeons 10/27/2014
Clementia Announces Open-Label Phase 2 Extension Study Of Palovarotene In Patients With Fibrodysplasia Ossificans Progressiva 10/27/2014
Ablynx (ABLYF)'s Ant-Il-6R Nanobody Partnered With AbbVie (ABBV) Demonstrates A Bioavailability Of More Than 80% After Subcutaneous Injection 10/23/2014
Oramed Pharmaceuticals Inc. (ORMP) Reports Positive Top-Line Data From U.S. Phase 2a Trial With Oral Insulin In Type 1 Diabetes 10/22/2014
Nuvo Research Inc. (NRI.TO) Completes WF10™ U.S. Market Study For Treatment Of Refractory Allergies 10/22/2014
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Designation From European Medicines Agency For The Treatment Of Dravet Syndrome 10/22/2014
Maxwell Biotech Portfolio Company Hepatera Announces Proof-Of-Concept Clinical Results With Myrcludex B, A Novel Entry Inhibitor For Treatment Of Chronic Hepatitis B And Delta 10/21/2014
TWi Biotechnology Receives Orphan Drug Designation For Its Lead Drug Candidate AC-201 In United States 10/21/2014
Norgine Release: Positive Results From Phase 2 Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 10/20/2014
Nanobiotix Receives First Approval To Start Phase 2/3 Registration Trial In Soft Tissue Sarcoma In Europe 10/16/2014
Cannabis Biopharma GW Pharmaceuticals Sees Disappointing Data For Colitis Drug 10/15/2014
Tekmira (TKMR)'s Partner Reports Positive Clinical Data For LNP-Enabled Patisiran 10/15/2014
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014
EU-Funded Consortium Led By immatics biotechnologies GmbH And BioNTech To Advance A Novel Class Of Fully Personalized Therapeutic Cancer Vaccines Into Clinical Trials For Brain Cancer 10/14/2014
Medivir AB (MVRBF): Phase 2 IMPACT Study Initiated To Evaluate Simeprevir In Combination With Sofosbuvir And Daclatasvir To Treat Genotype 1 And 4 Hepatitis C Patients 10/10/2014
Biotron Limited (BIT:AU) Release: BIT225 Trial Results Show Effective Cure Of Hepatitis C 10/10/2014



//-->